<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1570">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843878</url>
  </required_header>
  <id_info>
    <org_study_id>844488</org_study_id>
    <nct_id>NCT04843878</nct_id>
  </id_info>
  <brief_title>COVID-19 Testing Pilot Study</brief_title>
  <official_title>Feasibility Testing of a New COVID-19 Testing Platform</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Benjamin S. Abella, MD, MPhil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marcelo Der Torossian Torres, Ph.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cesar De La Fuente, Ph.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the reliability of a low-cost rapid diagnostic test&#xD;
      for COVID-19. The method of the testing procedure uses electrochemistry to detect COVID-19&#xD;
      spike proteins within human samples. To test the effectiveness of this new method, patients&#xD;
      will be recruited as they present for testing at ambulatory Penn testing sites. Patients will&#xD;
      be asked to self-collect one anterior nares samples under the supervision of authorized study&#xD;
      personnel.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2021</start_date>
  <completion_date type="Actual">March 12, 2021</completion_date>
  <primary_completion_date type="Actual">March 12, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Device Accuracy - Positive and Negative Percentage</measure>
    <time_frame>3 Months</time_frame>
    <description>The accuracy of the new prototype testing method will be determined by comparing the prototype's result to the clinical gold standard PCR test. The accuracy will be determined by calculating the percentage of the test's ability to correctly identify both the presence and absence of virus compared to the PCR result for the positive and negative results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device Accuracy - False positive and False negative percentage</measure>
    <time_frame>3 Months</time_frame>
    <description>The accuracy of the test will also be determined based on the percentage of false-positives and false-negatives compared to the gold standard clinical PCR test.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">326</enrollment>
  <condition>Diagnostic Test, Routine</condition>
  <condition>Coronavirus</condition>
  <condition>Diagnoses Disease</condition>
  <condition>Rapid Coronavirus Test</condition>
  <arm_group>
    <arm_group_label>Positive</arm_group_label>
    <description>Subjects that tested positive for COVID-19 based on the clinical gold standard PCR test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative</arm_group_label>
    <description>Subjects that tested negative for COVID-19 based on the clinical gold standard PCR test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>COVID Detect</intervention_name>
    <description>The study is determining the efficacy of a new rapid COVID testing method.</description>
    <arm_group_label>Negative</arm_group_label>
    <arm_group_label>Positive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited as they present for treatment at ambulatory Penn testing sites.&#xD;
        Subjects who present with symptoms of COVID-19-like illness at the study site as defined in&#xD;
        Inclusion Criteria below and have come to the study site for routine evaluation of their&#xD;
        condition may be enrolled in this clinical study. Males and females aged &gt;17 years old may&#xD;
        be enrolled, and should be represented in proportions representative of the population.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject must be an adult (age&gt;17) and either sex.&#xD;
&#xD;
          2. Written informed consent must be obtained prior to study enrollment.&#xD;
&#xD;
             a. A subject who is eighteen (18) years or older must be willing to give written&#xD;
             informed consent and must agree to comply with study procedures.&#xD;
&#xD;
          3. Subject must be able to read and write in English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject is currently receiving or has received within the past thirty (30) days of&#xD;
             the study visit an experimental biologic, drug, or device including either treatment&#xD;
             or therapy.&#xD;
&#xD;
          2. The subject has previously participated in this research study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin S Abella, MD, MPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2021</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Detect</keyword>
  <keyword>Pandemic</keyword>
  <keyword>Symptomatic</keyword>
  <keyword>Asymptomatic</keyword>
  <keyword>Anterior Nares</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plans to share IPD.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

